Status:
UNKNOWN
Semen Analysis Parameters Following Pfizer's COVID-19 Vaccine
Lead Sponsor:
Sheba Medical Center
Conditions:
Covid19
Fertility Issues
Eligibility:
MALE
18-45 years
Brief Summary
In this study the investigators will explore the effect of the BNT162b2 COVID-19 Vaccine on semen analysis parameters among 75 fertile men. Fertile men will be regarded as such if they previously succ...
Detailed Description
The 2019 novel coronavirus disease (COVID-19) is a highly infectious respiratory tract disease which was first reported in Wuhan, Hubei Province, China in Dec 2019, but has since spread globally. By m...
Eligibility Criteria
Inclusion
- Previously impregnated their partner without the use of assisted reproduce technology, or previously had a normal sperm analysis exam by WHO 2010 criteria.
- 1-2 months following the second dose of BNT162b2 COVID-19 Vaccine.
Exclusion
- Known abnormal semen parameters.
- Age above 45.
Key Trial Info
Start Date :
February 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04778033
Start Date
February 9 2021
End Date
May 1 2021
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba medical center
Ramat Gan, Israel